Exozymes Inc.: chief commercial officer Perriman Damien Alan sold 3,729 shares

What happened Perriman Damien Alan, chief commercial officer, converted 3,922 restricted stock units into common stock on Oct 9, 2026, and sold 3,729 shares in the open market on Oct 12, 2026 for total proceeds of $19,427. The Form 4 also reports a derivative disposition of 3,922 shares on Oct 9, 2026 at $0.00.

Key details

• Transaction dates and prices: Oct 9, 2026 conversion/exercise of 3,922 RSUs (no consideration paid per filing); Oct 12, 2026 sale of 3,729 shares at a weighted average price of $5.21, proceeds $19,427. Footnote states sale prices ranged from $5.15 to $5.25 across multiple trades.
• Shares owned after the transaction: not specified in the filing excerpt.
• Relevant footnotes: F1—RSUs convert one-for-one with no payment by the reporting person; F2—62,759 RSUs were granted on Apr 1, 2026 vesting periodically; F3—3,729 shares were sold to cover tax withholding obligations, sale effected in multiple trades (prices $5.15–$5.25).
• Filing timeliness: Form filed Oct 26, 2026 for transactions on Oct 9 and Oct 12, 2026 (filed after the transactions).

Why it may matter

• The filing shows conversion of restricted stock units and a subsequent sale to cover tax withholding; the sale was effected in multiple trades.
• The filing does not show why the insider traded or why the company acted.